Core Viewpoint - Creative Medical Technology Holdings, Inc. has entered into agreements for the immediate exercise of existing warrants, which will generate approximately 4.42 per share, originally issued in October 2024 [1]. - In exchange for the immediate exercise of existing warrants, the company will issue new unregistered warrants for up to 1,674,208 shares at an exercise price of $3.75 per share, exercisable for five years after shareholder approval [2]. - The transaction is expected to close on or about March 6, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the warrant exercise will be utilized for working capital and general corporate purposes [3]. Group 3: Regulatory Information - The new warrants and the shares issuable upon their exercise are offered in a private placement and have not been registered under the Securities Act of 1933 [4]. - The company plans to file a registration statement with the SEC for the resale of shares issuable upon the exercise of the new warrants [4]. Group 4: Company Overview - Creative Medical Technology Holdings, Inc. is a biotechnology company focused on advancing novel biological therapeutics in various medical fields, including immunotherapy and orthopedics, and is listed on NASDAQ under the ticker symbol CELZ [6].
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds